Header Logo

Connection

Paul Ruff to Middle Aged

Back to Details
This is a "connection" page, showing publications Paul Ruff has written about Middle Aged.
Paul Ruff
Connection Strength
1,215
Middle Aged
  1. It's contrary - comorbidity does not affect survival of South Africans with colorectal cancer: An analysis from the Colorectal Cancer in South Africa cohort. S Afr Med J. 2020 Apr 29; 110(5):382-388.
    View in: PubMed
    Score: 0,097
  2. Colorectal Cancer (CRC) treatment and associated costs in the public sector compared to the private sector in Johannesburg, South Africa. BMC Health Serv Res. 2020 Apr 07; 20(1):290.
    View in: PubMed
    Score: 0,097
  3. A Prospective Cohort Study of Factors Associated With Place of Death Among Patients With Late-Stage Cancer in Southern Africa. J Pain Symptom Manage. 2019 05; 57(5):923-932.
    View in: PubMed
    Score: 0,089
  4. Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIV. Breast. 2019 Feb; 43:123-129.
    View in: PubMed
    Score: 0,088
  5. Breast cancer survival in Soweto, Johannesburg, South Africa: A receptor-defined cohort of women diagnosed from 2009 to 11. Cancer Epidemiol. 2018 02; 52:120-127.
    View in: PubMed
    Score: 0,083
  6. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol. 2018 01; 9(1):32-39.
    View in: PubMed
    Score: 0,081
  7. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol. 2009 Sep; 64(4):763-8.
    View in: PubMed
    Score: 0,045
  8. The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort study. Lancet Glob Health. 2024 Dec; 12(12):e1993-e2002.
    View in: PubMed
    Score: 0,033
  9. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One. 2024; 19(11):e0309778.
    View in: PubMed
    Score: 0,033
  10. The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa. Breast Cancer Res Treat. 2023 Feb; 197(3):647-659.
    View in: PubMed
    Score: 0,029
  11. Impact of HIV infection on survival among women with stage I-III breast cancer: Results from the South African breast cancer and HIV outcomes study. Int J Cancer. 2022 Jul 15; 151(2):209-221.
    View in: PubMed
    Score: 0,028
  12. Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa. Breast Cancer Res Treat. 2021 Aug; 189(1):285-296.
    View in: PubMed
    Score: 0,026
  13. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol. 2020 10; 159(1):142-149.
    View in: PubMed
    Score: 0,025
  14. Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV. BMC Gastroenterol. 2020 Jul 13; 20(1):226.
    View in: PubMed
    Score: 0,025
  15. Breast Cancer Care Quality in South Africa's Public Health System: An Evaluation Using American Society of Clinical Oncology/National Quality Forum Measures. J Glob Oncol. 2019 11; 5:1-16.
    View in: PubMed
    Score: 0,023
  16. The multimorbidity profile of South African women newly diagnosed with breast cancer. Int J Cancer. 2020 07 15; 147(2):361-374.
    View in: PubMed
    Score: 0,023
  17. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy. Oncologist. 2019 07; 24(7):933-944.
    View in: PubMed
    Score: 0,022
  18. Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. Clin Cancer Res. 2019 02 15; 25(4):1216-1225.
    View in: PubMed
    Score: 0,022
  19. Illness Understanding and End-of-Life Care Communication and Preferences for Patients With Advanced Cancer in South Africa. J Glob Oncol. 2018 09; 4:1-9.
    View in: PubMed
    Score: 0,022
  20. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2018; 107(3):237-245.
    View in: PubMed
    Score: 0,021
  21. Informal Caregiver Challenges for Advanced Cancer Patients During End-of-Life Care in Johannesburg, South Africa and Distinctions Based on Place of Death. J Pain Symptom Manage. 2018 07; 56(1):98-106.
    View in: PubMed
    Score: 0,021
  22. Barriers to early presentation of breast cancer among women in Soweto, South Africa. PLoS One. 2018; 13(2):e0192071.
    View in: PubMed
    Score: 0,021
  23. A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Ann Oncol. 1998 Feb; 9(2):217-9.
    View in: PubMed
    Score: 0,021
  24. Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa. PLoS One. 2017; 12(8):e0182125.
    View in: PubMed
    Score: 0,020
  25. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer. 2016 11; 68:51-59.
    View in: PubMed
    Score: 0,019
  26. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 06; 11(3):383-400.
    View in: PubMed
    Score: 0,019
  27. Lymphoproliferative malignancies in association with endemic African Kaposi's sarcoma. Cent Afr J Med. 1994 Jul; 40(7):176-8.
    View in: PubMed
    Score: 0,016
  28. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May; 15(6):569-79.
    View in: PubMed
    Score: 0,016
  29. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology. 1994 Jan-Feb; 51(1):113-8.
    View in: PubMed
    Score: 0,016
  30. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan; 50(2):320-31.
    View in: PubMed
    Score: 0,015
  31. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 01; 30(28):3499-506.
    View in: PubMed
    Score: 0,014
  32. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 01; 28(31):4697-705.
    View in: PubMed
    Score: 0,013
  33. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 02; 360(14):1408-17.
    View in: PubMed
    Score: 0,011
  34. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int J Cancer. 2008 May 15; 122(10):2260-5.
    View in: PubMed
    Score: 0,011
  35. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20; 25(21):3069-75.
    View in: PubMed
    Score: 0,010
  36. Amyloidosis: a changing clinical perspective. Hematology. 2007 Apr; 12(2):163-7.
    View in: PubMed
    Score: 0,010
  37. A phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy. Int J Gynecol Cancer. 2006 Jul-Aug; 16(4):1614-9.
    View in: PubMed
    Score: 0,009
  38. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 2004 Jul 16; 4:36.
    View in: PubMed
    Score: 0,008
  39. Risk factors for high anti-HHV-8 antibody titers (> or =1:51,200) in black, HIV-1 negative South African cancer patients: a case control study. BMC Infect Dis. 2003 Sep 12; 3:21.
    View in: PubMed
    Score: 0,008
  40. The spectrum of HIV-1 related cancers in South Africa. Int J Cancer. 2000 Nov 01; 88(3):489-92.
    View in: PubMed
    Score: 0,006
  41. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol. 1997 Dec; 20(6):605-8.
    View in: PubMed
    Score: 0,005
  42. Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Br J Cancer. 1997; 75(11):1704-7.
    View in: PubMed
    Score: 0,005
  43. SSCP analysis of the tyrosine kinase domain of the insulin receptor gene: polymorphisms detected in South African black and white subjects. Hum Genet. 1996 Apr; 97(4):438-40.
    View in: PubMed
    Score: 0,005
  44. Radiation therapy in an elderly African population with Kaposi's sarcoma. Tumori. 1994 Apr 30; 80(2):139-40.
    View in: PubMed
    Score: 0,004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.